Adult Malignant Glioma Therapeutics Market: Business Challenges, Emerging Technologies & Competitive Landscape

Adult Malignant Glioma Therapeutics Market: Overview

Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there has been a consistent rise in the number of people diagnosed with malignant glioma. The American Brain Tumor Association has estimated around 69,720 new cases of brain tumor in 2013. Thus, rising number of people diagnosed with malignant glioma supports the growth of the global adult malignant glioma therapeutics market. Headache, physical weakness, memory loss and seizures are some of the common symptoms of malignant glioma. Thus, with symptoms getting worse size of tumor increases that destroys brain cells, creates swelling in the brain and increases the pressure on skull.

Obtain Report Details: http://www.transparencymarketresearch.com/adult-malignant-glioma-therapeutics-market.html

The global malignant glioma market can be segmented as follows:

  • By Type of Cell
    • Astrocytoma
    • Oligodendroglioma
    • Ependymoma
    • Unspecified Glioma
  • By Grade
    • Low – grade Gliomas
    • High – grade Gliomas
  • By Location
    • Supratentorial
    • Infratentorial

Cancer Research U.K. estimated that around 45% of the total primary brain tumor cases are gliomas. There are majorly four types of gliomas such as astrocytoma, oligodendroglioma, ependymoma and unspecified glioma. Astrocytoms is the most common type of glioma diagnosed globally, more than 30% of the total cases diagnosed with brain tumors are astrocytomas. These types of tumors are not curable as they spread easily through normal brain tissue. Astrocytomas are primarily classified on the basis of grades from one to four as per the speed of their growth in brain cells. American Brain Tumor Association have analyzed that around 7% of all the primary brain tumors represent astrocytomas.

Hence, a rising number of people diagnosed with astrocytomas accentuates the uptake of therapeutics for the treatment of the same. Currently, majority of the therapeutics for the treatment of malignant glioma is under clinical trials, key players are engaged in research and development activities.

Adult Malignant Glioma Therapeutics Market: Region-wise Insight

Geographically, North America and Europe accounted for the largest share in the global adult malignant glioma therapeutics market. This dominance was mainly attributed to key players domiciled in these regions coupled with increasing incidences of brain tumor. Brain tumor is the third most common type of cancer in adults in North America. According to North America Brain Tumor Coalition over 44,500 people in the U.S. were diagnosed with primary tumor in the brain in 2014. Thus, rising incidences of primary brain tumor supports the growth of malignant glioma therapeutics market in North America. In addition, increasing healthcare awareness also supported the growth of malignant glioma therapeutics market in North America and European market.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13211

Similarly, Asia Pacific is considered as the most lucrative market for the growth of malignant glioma therapeutics. The growth in Asian market is fueled by the presence of untapped market opportunities due to increasing and expanding healthcare infrastructure in this region. Asia Pacific is considered as an emerging market owing to growing market penetration coupled with increasing number of manufacturers expanding their geographic presence in this region. Thus, all the mentioned factors collectively propel the growth of malignant glioma therapeutics market during the forecast period from 2014 to 2020.

Adult Malignant Glioma Therapeutics Market: Key Players

Major players and universities engaged in the development of therapeutics for the treatment of malignant glioma include Eli Lilly and Company, Insys Therapeutics, Inc., GlaxoSmithKline plc, Amgen, Inc., Duke University, Shinshu University, Medical Research Council, Osaka University and others.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: